Rare diseases
Investigational molecules
Locations
Route De Perreux 1, 2017
Clinical research in Crohn's disease and ulcerative colitis centers on maintenance of remission, endoscopic response, and long-term control of moderate to severe intestinal inflammation. The portfolio also includes studies in pediatric Crohn's disease, with attention to clinical and endoscopic outcomes.
These programs reflect a focus on chronic gastrointestinal inflammation and disease control across adult and pediatric populations.
Celgene International II S.a.r.l. runs clinical trials in conditions such as Crohn's disease, Plasma cell myeloma, Eosinophilic oesophagitis, Colitis ulcerative, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Study on Alnuctamab and Mezigdomide for Patients with Relapsed or Refractory Multiple Myeloma
DenmarkStudy of Oral Ozanimod as Maintenance Treatment for Adults with Moderate to Severe Crohn's Disease
BelgiumStudy on Long-Term Safety of Cendakimab for Adults and Adolescents with Eosinophilic Esophagitis
AustriaStudy on the Long-Term Safety and Efficacy of Oral Ozanimod for Patients with Moderate to Severe Crohn's Disease
BulgariaStudy on the Long-Term Safety and Effectiveness of Ozanimod for Adults with Moderate to Severe Ulcerative Colitis
BelgiumStudy on the Effects of Ozanimod for Children with Moderate to Severe Crohn's Disease Not Responding to Usual Treatments
BelgiumStudy on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma
AustriaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
